WALTHAM, Mass.--(BUSINESS WIRE)--Entasis Therapeutics, a company focused on the discovery and development of breakthrough anti-infective products, today announced that preclinical data from ETX2514, a next-generation beta-lactamase inhibitor, will be presented at the first annual American Society for Microbiology (ASM) Microbe 2016 conference taking place June 16 through 20, 2016 in Boston.
Details of the presentations are as follows:
| Title: ETX2514, a Novel, Rationally Designed Inhibitor of Class A, C & D Beta-lactamases, for the Treatment of Gram-negative Infections |
| Session: 033 - Friday Late-Breaker Poster Presentations |
| Date: June 17, 2016 |
| Time: 12:30 – 2:30 pm ET |
| Poster Location: Boston Convention and Exhibition Center, Exhibit Hall A |
| Poster Number: LB-024 |
| Title: Addressing the Evolving Challenge of Beta-lactamase Mediated Antimicrobial Resistance: ETX2514, a Next-generation BLI with Potent, Broad Spectrum Activity Against Class A, C & D Enzymes |
| Session: 089 – Early New Antimicrobial Agents Oral Presentations |
| Date: June 17, 2016 |
| Time: 2:45 – 5:15 pm ET |
| Presentation Location: Boston Convention and Exhibition Center, Grand Ballroom West |
| Title: In Vitro and In Vivo Efficacy of the Novel Beta-lactamase Inhibitor ETX2514 Combined with Sulbactam Against Multidrug Resistant Acinetobacter baumannii |
| Session: 393 - Monday Late-Breaker Poster Presentations |
| Date: June 20, 2016 |
| Time: 12:30 – 2:30 pm ET |
| Poster Location: Boston Convention and Exhibition Center, Exhibit Hall A |
| Poster Number: LB-117 |
About ETX2514
ETX2514 is a broad and potent inhibitor of class A, C, and D beta-lactamases. Acinetobacter baumannii is a Gram-negative bacterium that causes severe infections which are associated with high mortality. A. baumannii infections are frequently multi-drug resistant and there is an urgent need to identify new agents to treat these infections. Sulbactam is a beta-lactam antimicrobial which has intrinsic activity against A. baumannii, but beta-lactamase-mediated resistance to sulbactam is now widespread. In preclinical studies, ETX2514 restores sulbactam’s antimicrobial activity. Entasis Therapeutics is developing the combination of sulbactam and ETX2514 for the treatment of severe A. baumannii infections.
About Entasis Therapeutics Inc.
Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Our deep pipeline of fundamentally innovative clinical and preclinical anti-infective programs is designed to revolutionize the way physicians treat serious bacterial diseases. www.entasistx.com
Contacts
Entasis Therapeutics
Christopher White, 781-810-0114
Chief Business Officer
Chris.White@entasistx.com
or
Media:
MacDougall Biomedical Communications
Julia Ogier, 781-235-3060
JOgier@macbiocom.com
